Avantor (AVTR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
Annual Meeting scheduled for May 7, 2026, will be held virtually; shareholders as of March 13, 2026, are eligible to vote on key proposals including director elections, executive compensation, and auditor ratification.
Major leadership transitions in 2025: Emmanuel Ligner appointed CEO in August 2025, Gregory Summe became Chairman in January 2026, and three new independent directors joined the Board.
The Revival program was launched to enhance competitiveness, optimize the portfolio, invest in manufacturing and supply chain, simplify operations, and strengthen talent and accountability.
2025 financial highlights: $6.55B revenue, $1.07B adjusted EBITDA, $496M free cash flow, and $0.90 adjusted EPS.
Voting matters and shareholder proposals
Shareholders will vote on electing nine directors for one-year terms, advisory approval of executive compensation, frequency of future say-on-pay votes (recommended annually), and ratification of Deloitte & Touche LLP as auditor for 2026.
Board recommends voting “FOR” all proposals and “ONE YEAR” for say-on-pay frequency.
Board of directors and corporate governance
Board reduced from twelve to nine members; eight of nine nominees are independent.
Board leadership is separated: independent Chairman and CEO roles.
Annual elections, majority voting standard, proxy access, and a 20% threshold for shareholders to call special meetings.
Robust Board and committee self-evaluations, director orientation, and ongoing education.
Policies prohibit short sales, hedging, and pledging of stock by directors and officers.
Latest events from Avantor
- Key votes include board elections, executive pay, and auditor ratification for 2026.AVTR
Proxy filing27 Mar 2026 - Q3 2025 net loss of $711.8M on 5.3% lower sales; $500M buyback and cost actions announced.AVTR
Q3 202517 Mar 2026 - 2026 is a transition year with Revival investments, margin pressure, and strong free cash flow.AVTR
Q4 202511 Feb 2026 - Q2 2024 saw margin expansion, net income rebound, and reaffirmed full-year guidance.AVTR
Q2 20242 Feb 2026 - Cost transformation and innovation drive margin expansion and resilience amid cautious demand.AVTR
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Cost transformation and bioprocessing momentum support a positive growth outlook.AVTR
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 2024 saw $1.71B revenue, strong cash flow, and raised FCF guidance amid cost transformation.AVTR
Q3 202418 Jan 2026 - Revival program and capital strategy accelerate transformation and global leadership.AVTR
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Bioprocessing and healthcare drive growth, with strong order trends and margin expansion into 2025.AVTR
7th Annual Evercore ISI HealthCONx Conference12 Jan 2026